Page 68 - Aet News Today

Women are in need of more menopause support through their employers, but many are reluctant to talk about it because of the stigma, said Alicia Jackson, CEO and founder of Evernow, during a panel discussion at HLTH.

Johnson & Johnson released research this month showing that its system for robotic-assisted bronchoscopy helped physicians achieve an over 15% improvement in overall diagnostic yield compared to traditional bronchoscopy. This could mean that fewer patients will have to “wait and see” while their cancer potentially gets worse.

Servier drug Tibsovo is now approved for treating advanced cases of myelodysplastic syndrome that have an IDH1 mutation. It’s the first approval of a targeted therapy for this type of cancer.

Elevance Health is finding ways to connect with the community in order to achieve better health equity.

HealthBook+ provides a way for individuals to aggregate and use their personal health information safely and securely to power AI engines that direct people to their next best health action. Importantly, it also gives employers predictive insights to help them provide the most relevant benefits for their employees.

The healthcare industry must prioritize the development and implementation of universal tools that can efficiently navigate, interpret, and derive value from the growing wealth of health data.

In the runup to the MedCity INVEST Digital Health conference, Christoph Besmer, a trade commissioner and head of investment promotion with Swiss Business Hub USA, talked about the “X Marks the Spot” campaign and how Switzerland Global Enterprise hopes to strengthen ties with U.S. health tech companies. 

Pair Team's $9 million Series A funding round was led by Next Ventures and included participation from PTX Capital, Create Health Ventures, OCA Ventures, CHCF Innovation Fund, Kapor Capital and other investors. In total, Pair Team has raised about $20 million.

Companies built for other businesses are attempting to offroad their skills into a brand new field. These fairweather healthcare players are unprepared for the terrain. Meanwhile, the true disruptors of this industry are already in it.

Abivax pulled off stock market deals in the U.S. and Europe that infuse the biotech with capital to continue clinical development of a small molecule for inflammation that’s differentiated from biologic therapies. In other biotech IPO news, Cargo Therapeutics and Invea Therapeutics both filed paperwork to go public.